Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib

Trial Profile

Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Pazopanib (Primary) ; Axitinib; Cabozantinib; Everolimus; Savolitinib; Sorafenib; Sunitinib; Temsirolimus
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms Spazo-2
  • Most Recent Events

    • 12 Sep 2017 Status changed from recruiting to active, no longer recruiting as per results presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results (n=285) of validation of the international metastatic database consortium (IMDC) prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib (1stPz) presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results of effectiveness of everolimus versus axitinib as a second-line after first-line pazopanib (n=189) presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top